May 15, 2026 12:12PM
May 15, 2026 12:11PM
May 7, 2026 07:00AM
May 5, 2026 07:01AM
May 5, 2026 07:00AM
Mar 25, 2026 06:57AM
Mar 24, 2026 07:00AM Amylyx completes enrollment in phase 3 trial for post-bariatric hypoglycemia
Mar 24, 2026 07:00AM
Mar 3, 2026 07:00AM
Dec 19, 2025 09:06AM
Dec 5, 2025 09:00AM
Dec 5, 2025 09:00AM
Nov 6, 2025 07:00AM
Oct 20, 2025 07:49AM Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar L
Oct 8, 2025 08:44AM
Aug 27, 2025 07:05AM
Aug 27, 2025 07:00AM
Aug 7, 2025 07:00AM
Jul 14, 2025 03:41PM
Jul 13, 2025 05:00PM
Jul 8, 2025 07:00AM Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
Jun 17, 2025 05:17AM
Jun 3, 2025 07:01AM
Jun 3, 2025 07:00AM
May 12, 2025 07:01AM
May 12, 2025 07:00AM
May 8, 2025 07:00AM
Apr 30, 2025 07:03AM Amylyx Pharmaceuticals (AMLX) Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
Apr 30, 2025 07:00AM
Mar 4, 2025 06:00AM
Jan 21, 2025 09:00AM
Jan 21, 2025 09:00AM
Jan 6, 2025 09:00AM
Dec 4, 2024 07:32AM
Dec 4, 2024 07:30AM Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
Nov 21, 2024 05:09AM
Nov 7, 2024 07:00AM
Oct 18, 2024 06:44AM
Oct 18, 2024 05:46AM
Oct 17, 2024 09:01AM
Oct 17, 2024 09:00AM
Aug 8, 2024 07:00AM Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
Aug 2, 2024 09:00AM
Jul 11, 2024 10:30AM
Jul 10, 2024 07:00AM
Jul 10, 2024 07:00AM
May 9, 2024 07:00AM
Apr 10, 2024 09:02AM
Apr 10, 2024 09:00AM Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Synd
Apr 4, 2024 07:02AM

322,096 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All